Phenotypes associated with this allele

• Allele Symbol: Slc2a2^tm2Thor
• Allele Name: targeted mutation 2, Bernard Thorens
• Allele ID: MGI:5514187
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Alb^tm1(cre/ERT2)Mtz/Alb^tm1(cre/ERT2)Mtz Slc2a2^tm2Thor/Slc2a2^tm2Thor	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6	MGI:5514226

Genotype
MGI:5514226

cn1

• Allelic Composition: Alb^{tm1(cre/ERT2)Mtz}/Alb^{tm1(cre/ERT2)Mtz}; Slc2a2^tm2Thor/Slc2a2^tm2Thor
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Suppressed hepatic glucose uptake in Slc2a2^tm2Thor/Slc2a2^tm2Thor Alb^{tm1(cre/ERT2)Mtz}/Alb^{tm1(cre/ERT2)Mtz} mice

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:197607 )

N • tamoxifen-treated mice exhibit normal energy homeostasis and plasma glucagon levels

abnormal glucose homeostasis ( J:197607 )

• tamoxifen-treated mice exhibit reduced hepatic glucose output and rate of glucose disappearance under basal but not insulin clamp conditions

decreased insulin secretion ( J:197607 )

• at 4 months following intraperitoneal glucose injection in tamoxifen-treated mice

• reduced insulin secretory capacity in islets of tamoxifen-treated mice

abnormal circulating glucose level ( J:197607 )

• rapid decrease of serum glucose levels early in the fasting period of tamoxifen-treated mice due to impaired hepatic glycogen mobilization

impaired glucose tolerance ( J:197607 )

• progressive development in tamoxifen-treated mice beginning at 4 months

abnormal glycogen homeostasis ( J:197607 )

• rapid decrease of serum glucose levels early in the fasting period of tamoxifen-treated mice due to impaired hepatic glycogen mobilization

increased liver glycogen level ( J:197607 )

• in fasted mice treated with tamoxifen

abnormal lipid homeostasis ( J:197607 )

• tamoxifen-treated mice exhibit increased VLDL production compared with control mice

• however, plasma triglycerides and cholesterol levels are normal

abnormal bile salt level ( J:197607 )

• decreased bile acid with altered composition in the feces of tamoxifen-treated mice

• however, serum levels are normal

decreased liver cholesterol level ( J:197607 )

• in fasted tamoxifen-treated mice

decreased liver triglyceride level ( J:197607 )

• in fasted mice treated with tamoxifen

cellular

increased skeletal muscle cell glucose uptake ( J:197607 )

• increased uptake in the extensor digitorum longus muscle of tamoxifen-treated mice during hyperinsulinemic clamp

decreased cellular glucose uptake ( J:197607 )

• in the liver of tamoxifen-treated mice

• however, fasted glucose production in the liver is normal

liver/biliary system

increased liver glycogen level ( J:197607 )

• in fasted mice treated with tamoxifen

decreased liver cholesterol level ( J:197607 )

• in fasted tamoxifen-treated mice

decreased liver triglyceride level ( J:197607 )

• in fasted mice treated with tamoxifen

muscle

increased skeletal muscle cell glucose uptake ( J:197607 )

• increased uptake in the extensor digitorum longus muscle of tamoxifen-treated mice during hyperinsulinemic clamp

endocrine/exocrine glands

decreased insulin secretion ( J:197607 )

• at 4 months following intraperitoneal glucose injection in tamoxifen-treated mice

• reduced insulin secretory capacity in islets of tamoxifen-treated mice